{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T10:59:45Z","timestamp":1776423585140,"version":"3.51.2"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1100,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1002\/hep.25872","type":"journal-article","created":{"date-parts":[[2012,5,31]],"date-time":"2012-05-31T18:13:31Z","timestamp":1338488011000},"page":"2363-2374","source":"Crossref","is-referenced-by-count":52,"title":["Cyclic AMP\/PKA-dependent paradoxical activation of Raf\/MEK\/ERK signaling in polycystin-2 defective mice treated with sorafenib"],"prefix":"10.1097","volume":"56","author":[{"given":"Carlo","family":"Spirli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carola M.","family":"Morell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Okolicsanyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy K.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Fabris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romina","family":"Fiorotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Strazzabosco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2012,8,27]]},"reference":[{"key":"10.1002\/hep.25872-BIB1|cit1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev.med.60.101707.125712","article-title":"Polycystic kidney disease","volume":"60","author":"Harris","year":"2009","journal-title":"Annu Rev Med"},{"key":"10.1002\/hep.25872-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1053\/j.gastro.2011.04.030","article-title":"Polycystic liver diseases: congenital disorders of cholangiocyte signaling","volume":"140","author":"Strazzabosco","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1002\/hep.25872-BIB3|cit3","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1002\/hep.24036","article-title":"Medical and surgical treatment options for polycystic liver disease","volume":"52","author":"Drenth","year":"1002","journal-title":"HEPATOLOGY"},{"key":"10.1002\/hep.25872-BIB4|cit4","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/hep.24723","article-title":"Altered store operated calcium entry increases cyclic 3\u2032,5\u2032-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective cholangiocytes","volume":"55","author":"Spirli","year":"2012","journal-title":"HEPATOLOGY"},{"key":"10.1002\/hep.25872-BIB5|cit5","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/hep.22636","article-title":"The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD)","volume":"49","author":"Banales","year":"2009","journal-title":"HEPATOLOGY"},{"key":"10.1002\/hep.25872-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1053\/j.gastro.2005.12.034","article-title":"Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism","volume":"130","author":"Gaudio","year":"2006","journal-title":"Gastroenterology."},{"key":"10.1002\/hep.25872-BIB7|cit7","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1053\/j.gastro.2009.09.005","article-title":"ERK1\/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice","volume":"138","author":"Spirli","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1002\/hep.25872-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/hep.23511","article-title":"Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice","volume":"51","author":"Spirli","year":"2010","journal-title":"HEPATOLOGY"},{"key":"10.1002\/hep.25872-BIB9|cit9","doi-asserted-by":"crossref","first-page":"C419","DOI":"10.1152\/ajpcell.00038.2007","article-title":"VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25\/-) mice","volume":"293","author":"Amura","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1002\/hep.25872-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1053\/j.gastro.2006.12.039","article-title":"Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3\u2032,5\u2032-cyclic monophosphate","volume":"132","author":"Masyuk","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1002\/hep.25872-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease","volume":"21","author":"Hogan","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1002\/hep.25872-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1136\/gut.2008.155721","article-title":"Somatostatin analogues reduce liver volume in polycystic liver disease","volume":"57","author":"van Keimpema","year":"2008","journal-title":"Gut"},{"key":"10.1002\/hep.25872-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1661-8.e1","DOI":"10.1053\/j.gastro.2009.07.052","article-title":"Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial","volume":"137","author":"van Keimpema","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1002\/hep.25872-BIB14|cit14","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0076-6879(05)07047-3","article-title":"Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature","volume":"407","author":"Adnane","year":"2006","journal-title":"Methods Enzymol"},{"key":"10.1002\/hep.25872-BIB15|cit15","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.1002\/hep.25872-BIB16|cit16","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00280-006-0393-4","article-title":"Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models","volume":"59","author":"Chang","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1002\/hep.25872-BIB17|cit17","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res"},{"key":"10.1002\/hep.25872-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/hep.21143","article-title":"Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases","volume":"43","author":"Fabris","year":"2006","journal-title":"HEPATOLOGY"},{"key":"10.1002\/hep.25872-BIB19|cit19","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease","volume":"10","author":"Torres","year":"2004","journal-title":"Nat Med"},{"key":"10.1002\/hep.25872-BIB20|cit20","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"key":"10.1002\/hep.25872-BIB21|cit21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2353\/ajpath.2008.070293","article-title":"Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney disease","volume":"172","author":"Alvaro","year":"2008","journal-title":"Am J Pathol"},{"key":"10.1002\/hep.25872-BIB22|cit22","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2353\/ajpath.2007.070073","article-title":"Analysis of liver repair mechanisms in Alagille syndrome and biliary atresia reveals a role for notch signaling","volume":"171","author":"Fabris","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1002\/hep.25872-BIB23|cit23","doi-asserted-by":"crossref","first-page":"F944","DOI":"10.1152\/ajprenal.00387.2010","article-title":"Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells","volume":"299","author":"Yamaguchi","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1002\/hep.25872-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/hep.23214","article-title":"Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2","volume":"50","author":"Blechacz","year":"2009","journal-title":"HEPATOLOGY"},{"key":"10.1002\/hep.25872-BIB25|cit25","doi-asserted-by":"crossref","first-page":"6861","DOI":"10.1038\/sj.onc.1208841","article-title":"The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006","volume":"24","author":"Yu","year":"2005","journal-title":"Oncogene"},{"key":"10.1002\/hep.25872-BIB26|cit26","doi-asserted-by":"crossref","first-page":"33637","DOI":"10.1074\/jbc.M503210200","article-title":"The anti-apoptotic protein Mcl-1 inhibits mitochondrial Ca2+ signals","volume":"280","author":"Minagawa","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1002\/hep.25872-BIB27|cit27","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1002\/hep.25872-BIB28|cit28","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.2174\/1381612023393026","article-title":"BAY 43-9006: preclinical data","volume":"8","author":"Wilhelm","year":"2002","journal-title":"Curr Pharm Des"},{"key":"10.1002\/hep.25872-BIB29|cit29","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"key":"10.1002\/hep.25872-BIB30|cit30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","article-title":"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF","volume":"140","author":"Heidorn","year":"2010","journal-title":"Cell"},{"key":"10.1002\/hep.25872-BIB31|cit31","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1053\/j.gastro.2010.04.010","article-title":"Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD","volume":"139","author":"Gradilone","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1002\/hep.25872-BIB32|cit32","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00432-006-0125-5","article-title":"Lysophosphatidylcholine suppresses apoptotic cell death by inducing cyclooxygenase-2 expression via a Raf-1 dependent mechanism in human cholangiocytes","volume":"132","author":"Gwak","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1002\/hep.25872-BIB33|cit33","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.molcel.2009.10.017","article-title":"C-Raf inhibits MAPK activation and transformation by B-Raf(V600E)","volume":"36","author":"Karreth","year":"2009","journal-title":"Mol Cell"},{"key":"10.1002\/hep.25872-BIB34|cit34","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1523-1755.2003.00755.x","article-title":"Renal activation of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease","volume":"63","author":"Nagao","year":"2003","journal-title":"Kidney Int"},{"key":"10.1002\/hep.25872-BIB35|cit35","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1046\/j.1523-1755.2003.00023.x","article-title":"Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys","volume":"63","author":"Yamaguchi","year":"2003","journal-title":"Kidney Int"}],"updated-by":[{"DOI":"10.1097\/hep.0000000000000485","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"record-id":"46217"},{"DOI":"10.1002\/hep.32537","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000}}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.25872","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/hep.25872\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T12:44:00Z","timestamp":1673441040000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hep.25872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,27]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.25872","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8,27]]}}}